CNMD - CONMED Corporation
96.02 0.00 (0.00%)
After hours: 4:36PM EDT
| Previous Close | 96.57 |
| Open | 96.29 |
| Bid | 96.00 x 800 |
| Ask | 96.00 x 900 |
| Day's Range | 95.03 - 97.50 |
| 52 Week Range | 56.91 - 97.50 |
| Volume | 180,661 |
| Avg. Volume | 214,676 |
| Market Cap | 2.717B |
| Beta (3Y Monthly) | 0.81 |
| PE Ratio (TTM) | 99.19 |
| EPS (TTM) | 0.97 |
| Earnings Date | Oct 30, 2019 - Nov 4, 2019 |
| Forward Dividend & Yield | 0.80 (0.84%) |
| Ex-Dividend Date | 2019-09-12 |
| 1y Target Est | 97.60 |
- Simply Wall St.
Have Insiders Been Selling CONMED Corporation (NASDAQ:CNMD) Shares?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
- Thomson Reuters StreetEvents
Edited Transcript of CNMD earnings conference call or presentation 31-Jul-19 8:30pm GMT
Q2 2019 Conmed Corp Earnings Call
- Business Wire
CONMED Corporation Announces Quarterly Cash Dividend
CONMED Corporation (CNMD) today announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on October 7, 2019 to all shareholders of record as of September 13, 2019. CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery, thoracic surgery and gastroenterology.
- Zacks
CONMED (CNMD) Q2 Earnings and Revenues Surpass Estimates
Higher revenues, solid segmental performance and strong adjusted gross margins benefit CONMED's (CNMD) Q2 earnings. However, high long-term debt remains a concern.
Motley FoolCONMED (CNMD) Q2 2019 Earnings Call Transcript
CNMD earnings call for the period ending June 30, 2019.
- Zacks
Conmed (CNMD) Surpasses Q2 Earnings and Revenue Estimates
Conmed (CNMD) delivered earnings and revenue surprises of 5.66% and 2.22%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
CONMED Corporation Announces Second Quarter 2019 Financial Results
CONMED Corporation today announced financial results for the second quarter of 2019.
- GuruFocus.com
Gains in Knee Replacement Driving Zimmer Biomet Growth
Shares near 52-week high after surpassing 2nd-quarter expectations Continue reading...
- Zacks
Conmed (CNMD) Reports Next Week: Wall Street Expects Earnings Growth
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
LH vs. CNMD: Which Stock Is the Better Value Option?
LH vs. CNMD: Which Stock Is the Better Value Option?
- Simply Wall St.
Do Investors Have Good Reason To Be Wary Of CONMED Corporation's (NASDAQ:CNMD) 0.9% Dividend Yield?
Could CONMED Corporation (NASDAQ:CNMD) be an attractive dividend share to own for the long haul? Investors are often...
- Zacks
Here's Why You Should Invest in CONMED (CNMD) Stock Now
CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D.
- Zacks
Myriad Genetics' Elevate 2020 Plan Holds Promise Amid Issues
Myriad Genetics (MYGN) unveils an 'Elevate 2020' program that aims to generate $50 million in incremental operating income by fiscal 2020.
- Zacks
Medtronic's Titan Spine Buyout to Boost Spine Surgery Range
Medtronic's (MDT) comprehensive biologics portfolio clubbed with Titan Spine's surface-enhanced titanium implants can enhance patient outcomes in spinal procedures.
- Business Wire
CONMED Corporation to Announce Second Quarter 2019 Financial Results on July 31, 2019
CONMED Corporation (CNMD) today announced that it will report financial results for the second quarter of 2019 after the market close on Wednesday, July 31, 2019. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call, dial 844-889-7792 (domestic) or 661-378-9936 (international) and refer to the passcode 6992059.
- Zacks
Walgreens Gains on Strategic Deals, Margin Pressure Remains
Walgreens Boots' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also benefiting from a strong retail prescription market.
- Zacks
Thermo Fisher's Unit Sale May Not Ail Specialty Diagnostics
The Anatomical Pathology business of Thermo Fisher (TMO) belongs to its Specialty Diagnostics segment that serves customers across healthcare and clinical laboratories.
- Zacks
Here's Why You Should Hold Varian Medical (VAR) Stock Now
Varian (VAR) expects the Cancer Treatment Services International buyout to prove accretive to earnings per share during fiscal 2021.
- Zacks
Amedisys Rides on New Buyouts, Strength in Personal Care Arm
Amedisys' (AMED) recently-integrated Personal Care segment is attaining stability and living up to expectation.
- Zacks
Veeva's Vault eTMF Implemented by South Korea's Celltrion
Management at Veeva (VEEV) expects Vault subscription revenues to grow a significant 40% in fiscal 2020.
- Simply Wall St.
A Closer Look At CONMED Corporation's (NASDAQ:CNMD) Uninspiring ROE
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- Zacks
Patterson Companies' (PDCO) Earnings Miss Estimates in Q4
Patterson Companies' (PDCO) Q4 results benefit from higher revenues, gross margin expansion and solid show by Animal Health segment.
- Zacks
Varian (VAR) & Tennessee Oncology to Implement Use of Noona
Varian's (VAR) core Oncology unit gets a boost from the latest collaboration with Tennessee Oncology.
- Zacks
Here's Why You Should Invest in DENTSPLY SIRONA (XRAY) Now
DENTSPLY (XRAY) focuses on innovation through active R&D.
- Zacks
Veeva's Submissions & RIM Implemented by Sumitomo Dainippon
Veeva's (VEEV) flagship Vault platform witnesses robust demand.
